UVX as an Adjuvant in the Treatment of Fungal Keratitis

Farabi Eye Hospital

Status: Unknown

Conditions: Treatment

Treatments: Radiation: CXL; Drug: topical voriconazole / levofloxacin systemic itraconazole

Study type: Interventional

Funder types: Other

Identifiers

NCT03138785

32768

Details and patient eligibility

About

In this study, investigators want to find the effect of adjuvant collagen cross-linking in the treatment of fungal keratitis

Enrollment: 20 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• fungal keratitis documented by culture or confocal scanning without any previous treatment

Exclusion criteria

• Previous treatment
• Thinning at presentation
• Perforation
• Associated with other microbial or viral keratitis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

20 participants in 2 patient groups

conventional treatment

Experimental group

Description:

In this arm, patients with documented fungal keratitis undergo conventional medical treatment.

Treatment:

Drug: topical voriconazole / levofloxacin systemic itraconazole

conventional treatment +CXL

Active Comparator group

Description:

In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day

Treatment:

Radiation: CXL

Drug: topical voriconazole / levofloxacin systemic itraconazole